Gene · 407014
Papers3,611
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,611
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches? | Cancers (Basel) | 2023 | 38067261 | PubTator, text mining | PubMed |
| Mechanism and Therapeutic Prospect of miRNAs in Neurodegenerative Diseases. | Behav Neurol | 2023 | 38058356 | PubTator, text mining | PubMed |
| Unlocking the power of nanomedicine: the future of nutraceuticals in oncology treatment. | Front Nutr | 2023 | 38045808 | PubTator, text mining | PubMed |
| Activation of the Nrf-2/HO-1 signalling axis can alleviate metabolic syndrome in cardiovascular disease. | Ann Med | 2023 | 38039549 | PubTator, text mining | PubMed |
| Translational control of furina by an RNA regulon is important for left-right patterning, heart morphogenesis and cardiac valve function. | Development | 2023 | 38032088 | PubTator, text mining | PubMed |
| Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers. | Front Pediatr | 2023 | 38027263 | PubTator, text mining | PubMed |
| FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies. | Front Pharmacol | 2023 | 38027013 | PubTator, text mining | PubMed |
| The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review. | Glob Med Genet | 2023 | 38025193 | PubTator, text mining | PubMed |
| Plant-Derived Epi-Nutraceuticals as Potential Broad-Spectrum Anti-Viral Agents. | Nutrients | 2023 | 38004113 | PubTator, text mining | PubMed |
| MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications. | Biomolecules | 2023 | 38002272 | PubTator, text mining | PubMed |
| MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype. | Biomedicines | 2023 | 38002007 | PubTator, text mining | PubMed |
| Molecular Biology and Clinical Management of Esophageal Adenocarcinoma. | Cancers (Basel) | 2023 | 38001670 | PubTator, text mining | PubMed |
Integrated Network Analysis of microRNAs, mRNAs, and Proteins Reveals the Regulatory Interaction between hsa-mir-200b and CFL2 Associated with Advanced Stage and Poor Prognosis in Patients with Intestinal Gastric Cancer. | Cancers (Basel) | 2023 | 38001634 | PubTator, text mining | PubMed |
| Identification of 3'-terminal 2'-O-methylated miRNA in plasma as a novel diagnostic biomarker of NSCLC. | Clin Transl Med | 2023 | 37997565 | PubTator, text mining | PubMed |
| Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression. | BMC Chem | 2023 | 37993971 | PubTator, text mining | PubMed |
| TP53 gene implications in prostate cancer evolution: potential role in tumor classification. | Med Pharm Rep | 2023 | 37970196 | PubTator, text mining | PubMed |
| Progress in the study of FOXO3a interacting with microRNA to regulate tumourigenesis development. | Front Oncol | 2023 | 37965449 | PubTator, text mining | PubMed |
| Stem cells and exosomes: as biological agents in the diagnosis and treatment of polycystic ovary syndrome (PCOS). | Front Endocrinol (Lausanne) | 2023 | 37964963 | PubTator, text mining | PubMed |
| Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications. | Cancers (Basel) | 2023 | 37958352 | PubTator, text mining | PubMed |
| Differential expression of serum miR-486 and miR-25 in ulcerative colitis and Crohn's disease: Correlations with disease activity, extent, and location. | Pathol Res Pract | 2023 | 37939427 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/407014/papers?page=6